Kristin Yarema to lead merged Inmagene-Ikena entity

Ahead of the planned closing of a deal that would unite Inmagene Biopharmaceuticals Co. Ltd. with Ikena Oncology Inc. (NASDAQ:IKNA), the organizations have chosen Kristin Yarema to lead the combined company as CEO. Yarema was president and CEO of Poseida Therapeutics Inc. during its final year before Roche (SIX:ROG; OTCQX:RHHBY) acquired it in a November 2024 deal.

Inmagene and Ikena said in December 2024 that they would unite, and their stockholders have approved the deal. An investor syndicate intends to invest $75 million in the combined entity, which is to be called ImageneBio Inc., trading on NASDAQ with the ticker IMA. Its lead program will be anti-OX40 antibody IMG-007, which is in Phase II testing to treat atopic dermatitis. ...